Literature DB >> 3378382

Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine.

T D Brewerton1, D L Murphy, E A Mueller, D C Jimerson.   

Abstract

In a study of serotonin (5-HT) function in patients with eating disorders and healthy control subjects, severe headaches with features of common migraine occurred unexpectedly in 28 of 52 subjects (54%) 8 to 12 hours after receiving a single oral dose of the 5-HT receptor agonist m-chlorophenylpiperazine (m-CPP), 0.5 mg/kg. None of the same subjects developed similar late-occurring headaches after placebo or the 5-HT precursor, L-tryptophan, 100 mg/kg given intravenously. The frequency of these migrainelike headaches was not significantly different between patients with bulimia or anorexia nervosa and control subjects, but incidence of headaches was significantly greater in subjects with a personal or family history of migraine, with almost all predisposed individuals (18 of 20, 90%) developing severe symptoms. Headache ratings were also significantly correlated (rho = 0.70; p less than 0.0001) with peak concentrations of m-CPP in plasma. These observations indicate that m-CPP may provide a novel probe for studies of the pathophysiology of migraine headaches.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3378382     DOI: 10.1038/clpt.1988.83

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.

Authors:  I Rainero; W Valfrè; L Savi; S Gentile; L Pinessi; L Gianotti; E Arvat; E Ghigo; P Del Rizzo; P Calvelli; P Limone
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

2.  Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Authors:  Matthew W Johnson; R Andrew Sewell; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

3.  Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.

Authors:  D L Murphy; E A Mueller; J L Hill; T J Tolliver; F M Jacobsen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  5-HT2 receptor antagonists and migraine therapy.

Authors:  E J Mylecharane
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 5.  5-Hydroxytryptamine and the pathophysiology of migraine.

Authors:  P P Humphrey
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 6.  Serotonin and migraine: a reconsideration of the central theory.

Authors:  Alessandro Panconesi
Journal:  J Headache Pain       Date:  2008-07-31       Impact factor: 7.277

7.  The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.

Authors:  A M Brown; T L Patch; A J Kaumann
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  The Effect of Paroxetine on the Reduction of Migraine Frequency is Independent of Its Anxiolytic Effect.

Authors:  Hyun-Jung Park; Soon-Tae Lee; Ji-Young Shim; Bomie Kim; Sun-Hee Hwang; Sook-Hee Kim; Jeong-Eun Park; Jong-Ha Park; Se-Hee Jung; Jin-Young Ahn; Kon Chu; Manho Kim
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

Review 9.  The role of nitric oxide in vascular headache.

Authors:  Paul-Hugo M van der Kuy; Joseph J Lohman
Journal:  Pharm World Sci       Date:  2003-08

10.  Functional gene variants of the serotonin-synthesizing enzyme tryptophan hydroxylase 2 in migraine.

Authors:  Martin Marziniak; Claudia Kienzler; Gregor Kuhlenbäumer; Claudia Sommer; Rainald Mössner
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.